慢性自发性荨麻疹发病过程中肥大细胞作用及其靶向治疗进展

doi:10.35541/cjd.20240291

中华皮肤科杂志 ›› 2024, e20240291.doi: 10.35541/cjd.20240291

• 综述 • 上一篇

慢性自发性荨麻疹发病过程中肥大细胞作用及其靶向治疗进展

许焯红¹ 周栩悦¹ 胡煜² 顾恒²

¹北京协和医学院中国医学科学院皮肤病医院皮肤病研究所，南京 210042；²中国医学科学院北京协和医学院皮肤病医院，南京 210042

收稿日期:2024-05-30 修回日期:2024-10-31 发布日期:2024-12-09
通讯作者: 胡煜;顾恒 E-mail:huyupumc@126.com; guheng@aliyun.com
基金资助:
国家自然科学基金（82273552、82203947、82304049）；中国医学科学院医学与健康科技创新工程（CIFMS-2021-I2M-1-001）；2023年北京协和医学院中央高校基本科研业务费（3332023172）

Role of mast cells in the pathogenesis of chronic spontaneous urticaria and advances in mast cell-targeted therapies

Xu Zhuohong¹, Zhou Xuyue¹, Hu Yu², Gu Heng²

¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Nanjing 210042, China; ²Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2024-05-30 Revised:2024-10-31 Published:2024-12-09
Contact: Hu Yu; Gu Heng E-mail:huyupumc@126.com; guheng@aliyun.com
Supported by:
National Natural Science Foundation of China （82273552, 82203947, 82304049）; CAMS Innovation Fund for Medical Sciences （CIFMS-2021-I2M-1-001）; Fundamental Research Funds for the Central Universities （3332023172）

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹（CSU）是一种主要由肥大细胞驱动的常见皮肤疾病，肥大细胞主要通过Ⅰ型和Ⅱb型自身免疫反应在CSU的发展中发挥作用。本文综述肥大细胞在CSU中的作用机制、靶向肥大细胞治疗CSU的新方法以及未来的研究方向，为临床治疗提供参考。

关键词: 慢性荨麻疹, 肥大细胞, 自身免疫, 抗体, 单克隆, 治疗, 临床研究性, 小分子药物

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is a common skin disorder primarily driven by mast cells. It has been found that mast cells play a crucial role in the development of CSU mainly through type Ⅰ and Ⅱb autoimmune responses. This review summarizes the mechanisms of action of mast cells in CSU, new methods of targeting mast cells for the treatment of CSU, and future research directions, providing a reference for the clinical treatment of CSU.

Key words: Chronic urticaria, Mast cells, Autoimmunity, Antibodies, monoclonal, Therapies, investigational, Small molecule drug

许焯红周栩悦胡煜顾恒. 慢性自发性荨麻疹发病过程中肥大细胞作用及其靶向治疗进展[J]. 中华皮肤科杂志, 2024,e20240291. doi:10.35541/cjd.20240291

Xu Zhuohong, Zhou Xuyue, Hu Yu, Gu Heng. Role of mast cells in the pathogenesis of chronic spontaneous urticaria and advances in mast cell-targeted therapies[J]. Chinese Journal of Dermatology,2024,e20240291. doi:10.35541/cjd.20240291

参考文献 42

［1］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
［2］	Dobrican CT, Muntean IA, Pintea I, et al. Immunological signature of chronic spontaneous urticaria （review）［J］. Exp Ther Med, 2022,23（6）:381. doi: 10.3892/etm.2022.11309.
［3］	Nakano N, Kitaura J. Mucosal mast cells as key effector cells in food allergies［J］. Cells, 2022,11（3）:329. doi: 10.3390/cells 11030329.
［4］	Reber LL, Sibilano R, Mukai K, et al. Potential effector and immunoregulatory functions of mast cells in mucosal immunity［J］. Mucosal Immunol, 2015,8（3）:444⁃463. doi: 10.1038/mi. 2014.131.
［5］	Elieh⁃Ali⁃Komi D, Metz M, Kolkhir P, et al. Chronic urticaria and the pathogenic role of mast cells［J］. Allergol Int, 2023,72（3）:359⁃368. doi: 10.1016/j.alit.2023.05.003.
［6］	Schmetzer O, Lakin E, Topal FA, et al. IL⁃24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2018,142（3）:876⁃882. doi: 10.1016/j.jaci.2017.10.035.
［7］	Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2022,149（6）:1819⁃1831. doi: 10.1016/j.jaci.2022.04.010.
［8］	Nagata Y, Suzuki R. FcεRI: a master regulator of mast cell functions［J］. Cells, 2022,11（4）:622. doi: 10.3390/cells1104 0622.
［9］	Kaplan A, Lebwohl M, Giménez⁃Arnau AM, et al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances［J］. Allergy, 2023,78（2）:389⁃401. doi: 10. 1111/all.15603.
［10］	Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high⁃affinity IgE receptor as a cause of histamine release in chronic urticaria［J］. N Engl J Med, 1993,328（22）:1599⁃1604. doi: 10.1056/NEJM199306033282204.
［11］	Asero R, Marzano AV, Ferrucci S, et al. Co⁃occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria［J］. Clin Exp Immunol, 2020,200（3）:242⁃249. doi: 10. 1111/cei.13428.
［12］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［13］	Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria［J］. N Engl J Med, 2013,368（10）:924⁃935. doi: 10.1056/NEJMoa 1215372.
［14］	Thomas D, McDonald VM, Stevens S, et al. Biologics （mepolizumab and omalizumab） induced remission in severe asthma patients［J］. Allergy, 2024,79（2）:384⁃392. doi: 10.1111/all.15867.
［15］	Yuan W, Hu S, Li M, et al. Efficacy and safety of omalizumab in Chinese patients with anti⁃histamine refractory chronic spontaneous urticaria［J］. Dermatol Ther, 2022,35（4）:e15303. doi: 10.1111/dth.15303.
［16］	Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti⁃IgE antibody ligelizumab differs from omalizumab［J］. Nat Commun, 2020,11（1）:165. doi: 10.1038/s41467⁃019⁃13815⁃w.
［17］	Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2019,381（14）:1321⁃1332. doi: 10.1056/NEJMoa1900408.
［18］	Kuo BS, Li CH, Chen JB, et al. IgE⁃neutralizing UB⁃221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23⁃mediated IgE downregulation and relieves urticaria symptoms［J］. J Clin Invest, 2022,132（15）:e157765. doi: 10.1172/JCI 157765.
［19］	Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria［J］. Ann Allergy Asthma Immunol, 2020,125（4）:380⁃387. doi: 10.1016/j.anai.2019.08.465.
［20］	Ramirez Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin［J］. Br J Pharmacol, 2019,176（8）:1135⁃1142. doi: 10.1111/bph.14610.
［21］	Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine⁃refractory chronic spontaneous urticaria: a randomized phase 2 trial［J］. Nat Med, 2021,27（11）:1961⁃1969. doi: 10.1038/s41591⁃021⁃01537⁃w.
［22］	Maurer M, Berger W, Giménez⁃Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2022,150（6）:1498⁃1506.e2. doi: 10.1016/j.jaci.2022.08.027.
［23］	Jain V, Giménez⁃Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks［J］. J Allergy Clin Immunol, 2024,153（2）:479⁃486.e4. doi: 10.1016/j.jaci.2023. 10.007.
［24］	Morales JK, Falanga YT, Depcrynski A, et al. Mast cell homeostasis and the JAK⁃STAT pathway［J］. Genes Immun, 2010,11（8）:599⁃608. doi: 10.1038/gene.2010.35.
［25］	Clauzure M, Táquez Delgado MA, Phillip JM, et al. Histamine H4 receptor agonism induces antitumor effects in human T⁃cell lymphoma［J］. Int J Mol Sci, 2022,23（3）:1378. doi: 10.3390/ijms23031378.
［26］	Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double⁃blind, placebo⁃controlled, multicenter, parallel⁃group study of a H4 R⁃antagonist （JNJ⁃39758979） in Japanese adults with moderate atopic dermatitis［J］. J Dermatol, 2015,42（2）:129⁃139. doi: 10.1111/1346⁃8138.12726.
［27］	Kollmeier AP, Barnathan ES, O'Brien C, et al. A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma［J］. Ann Allergy Asthma Immunol, 2018,121（5）:568⁃574. doi: 10.1016/j.anai.2018.08.001.
［28］	Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL⁃3893787 in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,143（5）:1830⁃1837.e4. doi: 10.1016/j.jaci.2018.07.047.
［29］	Oliver ET, Chichester K, Devine K, et al. Effects of an oral CRTh2 antagonist （AZD1981） on eosinophil activity and symptoms in chronic spontaneous urticaria［J］. Int Arch Allergy Immunol, 2019,179（1）:21⁃30. doi: 10.1159/000496162.
［30］	Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma （LUSTER⁃1 and LUSTER⁃2）: two phase 3 randomised controlled trials［J］. Lancet Respir Med, 2021,9（1）:43⁃56. doi: 10.1016/S2213⁃2600（20）30412⁃4.
［31］	Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1659⁃1661.e1. doi: 10.1016/j.jaip. 2018.11.018.
［32］	Abadeh A, Lee JK. Long⁃term follow⁃up of patients treated with dupilumab for chronic spontaneous urticaria: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221117702. doi: 10.1177/2050313X221117702.
［33］	Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY⁃CSU CUPID）: two randomized, double⁃blind, placebo⁃controlled, phase 3 trials［J］. J Allergy Clin Immunol, 2024,154（1）:184⁃194. doi: 10.1016/j.jaci.2024.01.028.
［34］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［35］	Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria［J］. Clin Exp Allergy, 2020,50（7）:799⁃804. doi: 10. 1111/cea.13616.
［36］	Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate⁃to⁃severe prurigo nodularis: a randomised, double⁃blind, placebo⁃controlled, phase 2a study［J］. EClinicalMedicine, 2023,57:101826. doi: 10.1016/j.eclinm.2023. 101826.
［37］	Menzies⁃Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma［J］. N Engl J Med, 2021,384（19）:1800⁃1809. doi: 10.1056/NEJMoa 2034975.
［38］	Alvarado D, Maurer M, Gedrich R, et al. Anti⁃KIT monoclonal antibody CDX⁃0159 induces profound and durable mast cell suppression in a healthy volunteer study［J］. Allergy, 2022,77（8）:2393⁃2403. doi: 10.1111/all.15262.
［39］	Wedi B. Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development［J］. Expert Opin Investig Drugs, 2023,32（11）:1043⁃1054. doi: 10.1080/13543784.2023. 2277385.
［40］	Karra L, Berent⁃Maoz B, Ben⁃Zimra M, et al. Are we ready to downregulate mast cells?［J］. Curr Opin Immunol, 2009,21（6）:708⁃714. doi: 10.1016/j.coi.2009.09.010.
［41］	Altrichter S, Staubach P, Pasha M, et al. An open⁃label, proof⁃of⁃concept study of lirentelimab for antihistamine⁃resistant chronic spontaneous and inducible urticaria［J］. J Allergy Clin Immunol, 2022,149（5）:1683⁃1690.e7. doi: 10.1016/j.jaci.2021.12.772.
［42］	Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell⁃mediated diseases［J］. Allergy, 2024,79（1）:37⁃51. doi: 10.1111/all.15850.

[1]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会老年皮肤病学组. [开放获取] 老年皮肤瘙痒症诊疗与康复专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 1-8.
[2]	中国康复医学会皮肤病康复专业委员会中国康复医学会光动力治疗与康复专业委员会中华医学会皮肤性病学分会光动力治疗协作组. [开放获取] 氨基酮戊酸光动力疗法治疗非黑色素瘤皮肤癌临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 9-19.
[3]	廖彩荷王佩茹吴明顺孙晓飞张国龙王秀丽. 联合氨基酮戊酸光动力疗法治疗老年颜面部基底细胞癌的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 34-39.
[4]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[5]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[6]	杨子靖陈利红阮叶平文莞廷张嘉艺王海伦潘萌赵肖庆. 度普利尤单抗治疗老年性特应性皮炎的疗效及安全性研究[J]. 中华皮肤科杂志, 2025, 58(1): 65-69.
[7]	王迪张瑞珺康玉英. 脂溢性皮炎的发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 89-92.
[8]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[9]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[10]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[11]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[12]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[13]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.
[14]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[15]	陈浩天刘莲张婷刘青锋李晓雪刁萍蒋献. 鲜红斑痣发病及进展机制研究进展[J]. 中华皮肤科杂志, 2024, 57(7): 661-664.

慢性自发性荨麻疹发病过程中肥大细胞作用及其靶向治疗进展

Role of mast cells in the pathogenesis of chronic spontaneous urticaria and advances in mast cell-targeted therapies

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

Metrics

本文评价

推荐阅读 10